Avila Teams With Leukemia Society

Xconomy Boston — 

Avila Therapeutics, the Waltham, MA-based drug developer, is announcing today it will receive as much as $3.2 million from The Leukemia & Lymphoma Society to support development of a new therapy for B-cell related cancers. The drug, AVL-292, is designed to form a tight covalent bond to hit a target on immune system B-cells, called Bruton’s Tyrosine Kinase, or Btk. Avila plans to take the product candidate into its first clinical trial in 2010. Avila CEO Katrine Bosley told me more about this drug and Avila’s hepatitis C treatment, in a feature story last month.